Review: predicting psychosis using blood biomarkers

1 Prognostic models predicting transition to psychotic disorder using blood-

- 2 based biomarkers: a systematic review and critical appraisal.
- 3
- 4 **Authors:** Jonah F. Byrne^{1,2}, BSc; David Mongan^{1,3}, MB PhD; Jennifer Murphy, MSc¹; Colm
- 5 Healy¹, PhD; Melanie Föcking^{1,2}, PhD; Mary Cannon^{1,2}, MB PhD; David R. Cotter^{1,2}, MB
- 6 PhD.
- ⁷ ¹Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland.
- ² SFI FutureNeuro Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
- ³ Centre for Public Health, Queen's University Belfast, United Kingdom.
- 10
- 11 Correspondence: Jonah Byrne
- 12 E-mail: jonahbyrne21@rcsi.ie
- 13 Address: Department of Psychiatry, Royal College of Surgeons in Ireland, Education and
- 14 Research Centre, Beaumont Hospital, Dublin 9, Ireland
- 15

Review: predicting psychosis using blood biomarkers

16 Abstract

17 Background

Accumulating evidence suggests individuals with psychotic disorder show abnormalities in metabolic and inflammatory processes. Recently, several studies have employed blood-based predictors in models predicting transition to psychotic disorder in risk-enriched populations. A systematic review of the performance and methodology of prognostic models using bloodbased biomarkers in the prediction of psychotic disorder from risk-enriched populations is warranted.

24 Methods

Databases (PubMed, EMBASE and PsycINFO) were searched for eligible texts from 1998 to 15/05/2023 which detailed model development or validation studies. The checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) was used to guide data extraction from eligible texts and the Prediction Model Risk of Bias Assessment Tool (PROBAST) was used to assess risk of bias and applicability of the studies. A narrative synthesis of included studies was performed.

31 Results

17 eligible studies were identified: 16 eligible model development studies and one eligible model validation study. A wide range of biomarkers were assessed including nucleic acids, proteins, metabolites and lipids. The range of C-index (area under the curve) estimates reported for the models was 0.67-1.00. No studies assessed model calibration. According to PROBAST criteria, all studies were at high risk of bias in the analysis domain.

37 Discussion

While a wide range of potentially predictive biomarkers were identified in the included studies, most studies did not account for overfitting in model performance estimates, no studies assessed calibration, and all models were at high risk of bias according to PROBAST criteria.

Review: predicting psychosis using blood biomarkers

External validation of the models is needed to provide more accurate estimates of their performance. Future studies which follow the latest available methodological and reporting guidelines and adopt strategies to accommodate required sample sizes for model development or validation will clarify the value of including blood-based biomarkers in models predicting psychosis.

46

47 Introduction

48 Background and Rationale

49 Recent research in the field of early intervention in psychosis has focused on building models 50 to predict the development of psychotic disorder [1-3]. These models have largely been 51 developed in "clinical high-risk" populations, which include individuals showing prodromal 52 symptoms or genetic risk combined with functional decline, as determined with validated 53 assessment tools such as the Comprehensive Assessment of At-Risk Mental State 54 (CAARMS) [4] and the Structured Interview for Prodromal Symptoms (SIPS) [5,6]. Meta-55 analytic estimates indicate 19% of individuals at clinical high-risk develop psychosis within two 56 years [7].

57 Accumulating evidence points towards abnormalities in metabolic and inflammatory 58 processes in individuals with psychosis [8–10] and there is some evidence to suggest that 59 these abnormalities may precede medication use [9] or even the onset of psychosis [11,12]. 60 The prognostic value of peripheral markers over lifestyle or environmental factors, such as 61 smoking and exercise, is unclear [13,14]. However, several studies have employed a range of 62 blood-based predictors in models predicting transition to psychotic disorder, with several 63 published since the last systematic reviews of models in the field [15–19]. A recent large-scale 64 systematic review included all prediction models in psychiatry, except those using biological 65 predictors [20]. Biological predictors have the advantage of often being more objective and 66 precise than, for example, scores given on symptom scales. Blood biomarkers are among the

Review: predicting psychosis using blood biomarkers

67 least invasive biological parameters, with relative low-cost. There is a clear pathway for their 68 integration into clinical practice, as they could be measured along with routine blood markers, 69 or predictors could consist of routine blood measures. As such, a systematic review of 70 prognostic models predicting transition to psychotic disorder using blood-based biomarkers is 71 warranted. Furthermore, the weak standard of prediction modelling methodology in psychiatry 72 and medicine in general has been highlighted previously, in particular regarding the need for 73 validation and implementation of models [20-22]. Therefore, a review of methodology that takes into account the interaction between the use of blood-based biomarkers and prediction 74 75 modelling may help future research in the field.

76 Objectives

To systematically review the performance and methodology of models predicting transition to psychotic disorder from risk-enriched populations, with a focus on those using blood-based biomarkers, to determine their potential utility in predictive models and to help guide future research in the field.

81

82 Methods

This review was reported using the guidelines for transparent reporting of multivariable prediction models for individual prognosis or diagnosis: systematic reviews and meta-analyses (TRIPOD-SRMA) [23].

86 Eligibility Criteria

Studies were eligible for inclusion if they; 1) described the development, validation or updating of a prognostic model of transition to psychotic disorder in "at-risk" (or similar psychosis riskenriched populations) help-seeking individuals, 2) used blood-based biomarkers in the prognostic model described, 3) were published in peer-reviewed journals, 4) were published after 1998 (after the first prospective studies using clinical high-risk criteria were published;

Review: predicting psychosis using blood biomarkers

[24]) and 5) had full-texts available in English. The PICOTS (Population, Intervention,
Comparator, Outcome, Timing, Setting) criteria were used to guide the development of
eligibility criteria and can be found in the Supplementary Material.

95 Studies were excluded if they focused on psychiatric disorders other than psychotic disorders 96 (for example studies solely focusing on prediction of depression) and if they investigated risk 97 factors or longitudinal associations but did not report the development and/or validation of a 98 risk prediction model. Studies that reported only on models including blood-based predictors 99 in combination with brain or cerebrospinal fluid biomarkers were excluded as the predictive 100 value of the blood-based biomarkers in the models would be difficult to determine precisely, 101 and as the aim of the review was to identify models that required the measurement of blood 102 biomarkers only, without the requirement for a further invasive and expensive procedure. 103 Studies must have had a binary outcome of transition to psychosis to be included in the current 104 study (studies predicting continuous outcomes were excluded, for example psychotic 105 symptom scales). Studies of continuous outcomes were excluded for several reasons, 106 including a) transition is the key outcome in the literature, b) the difficulty in implementing a 107 prediction model in clinical practice without a clear diagnostic outcome, c) individual clinical 108 scales (positive symptoms or negative symptom scales) can't define diagnosis alone, d) 109 potentially multiple different outcomes (functioning and clinical symptom subscales) that may 110 use multiple different non-comparable scales (e.g. the Positive And Negative Symptom Scale 111 and the Community Assessment of Psychic Experiences).

112

113 Information Sources and Search Strategy

PubMed, EMBASE and PsycINFO were searched from 01/01/1998 to 15/05/2023 using the following general search strategy: psychosis risk-enrichment keywords AND transition to psychotic disorder keywords AND prediction modelling keywords AND blood-based biomarker keywords. The search strategy was developed with the use of established strategies for

Review: predicting psychosis using blood biomarkers

searching for predictive modelling studies [25]. The full search strategies, as formatted for

each database, are included in the Supplementary Material.

120 In an attempt to find other references that may meet inclusion criteria, reference lists of 121 relevant reviews that appeared in the databases searched were examined and forward citation 122 searching was carried out on Google Scholar for texts eligible for full-text screening up to 123 01/06/2023. Where clearly eligible models were detailed in conference abstracts and 124 corresponding full-texts could not be found, we contacted the corresponding authors for 125 information on potential unpublished full-texts.

126

127 Selection Process

Duplicate records were identified with guidance from previous recommendations [26] and removed. Abstracts identified by the search strategy were screened independently by JFB, DM and JM. Prediction modelling studies that clearly did not meet the eligibility criteria were excluded and the full-texts of all other studies were examined. Disagreements were resolved through discussion and or by referral to a third author (DRC).

133

134 Data Collection Process

Data were extracted from studies using the CHARMS checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies [27]. Data were extracted independently by JFB, DM and JM. Disagreements were resolved through discussion or referral to a third author (CH or MF). Where several similar models were presented in studies (e.g. models with minor differences in predictors included), data pertaining to the final model as indicated by the study authors was extracted. Where study authors did not indicate a final model, data pertaining to the best performing model was extracted.

Review: predicting psychosis using blood biomarkers

As part of the CHARMS, we extracted two main model performance metrics: discrimination (how well the model differentiates between individuals who do and do not develop the outcome; the Concordance (C)-index [28], which is equivalent to the area-under-the-curve in the case of a binary outcome) and calibration (how well the predicted probabilities match the actual proportion of outcomes) [29], where available. Where studies reported on the added predictive value of blood-based biomarkers to models, relevant metrics and tests (such as the likelihood ratio chi-square test) of added predictive information were extracted, if available.

149

150 Risk of Bias and Applicability Assessment

151 Risk of bias assessments were carried out using the prediction model risk of bias assessment 152 tool (PROBAST) [30,31], which assesses risk of bias in the selection of participants, 153 measurement of predictors or outcomes and in the analysis. Using the PROBAST tool, 154 concerns of applicability of the study to the review question were also rated in the domains 155 selection of participants, measurement of predictors or measurement of outcomes. PROBAST 156 ratings for risk of bias and applicability assessments can be either high, low or unclear. 157 Assessments were carried out independently by JFB, DM and JM. Disagreements were 158 resolved through discussion with a third author (CH). PROBAST figures were generated using 159 the robvis package [32] in R (<u>https://github.com/mcguinlu/robvis</u>). Required sample sizes for 160 precise estimates of model performance on external validation were calculated in R 161 (https://github.com/c-qu/samplesize-validation) according to guidelines from a previous 162 publication [33].

163

164 Synthesis Methods

We planned to use a narrative synthesis method [34]. We stratified performance estimates of the included model development studies based on the PROBAST signalling question "Were model overfitting and optimism in model performance accounted for?". As per PROBAST

Review: predicting psychosis using blood biomarkers

168 guidance, model overfitting and optimism in model performance estimates were accounted for 169 if both internal validation and shrinkage techniques were applied, and if predictor selection 170 procedures (e.g. univariable screening or backwards selection) were included in the internal 171 validation framework [31]. Meta-analyses were to be carried out only if a particular model had 172 multiple external validation studies [35].

173

174 **Results**

175 Study Selection

176 A PRISMA flow diagram is presented in Figure 1. The database search identified 2,565 177 records. Following removal of duplicates, 1,677 titles and abstracts were screened, and 45 178 articles were brought forward for full-text screening. 13 records (relating to 13 studies) were 179 included, and 32 records were excluded. Reasons for exclusion can be summarised in the 180 following categories: not predictive modelling, no blood-based predictors used, ineligible study 181 design (participants or outcome do meet eligibility criteria), conference abstract only. We 182 contacted authors of three conference abstracts which detailed clearly eligible models for 183 further information on potential full-texts related to the abstracts. Authors of two conference 184 abstracts confirmed that both abstracts related to a single study for which we had already 185 obtained a peer-reviewed full-text. We did not receive a response from the authors of one 186 conference abstract which detailed a clearly eligible model.

Forward citation searching of the 45 full-texts identified eight further potentially eligible fulltexts, of which four were excluded (not predictive modelling) and four records (relating to four studies) were included (two of which were full-text reports of conference abstracts identified in the database search). Therefore, 17 studies were included overall.

191

Review: predicting psychosis using blood biomarkers

193 Study Characteristics

194 Of the 17 included studies, 16 were prognostic model development studies [15–19,36–46] and 195 one study was a prognostic model external validation study [47]. All studies were conducted 196 in outpatients. There were five models developed in the Shanghai At Risk for Psychosis 197 (SHARP) study [18,19] and the extension of that study [44–46]. There were three model 198 development studies each for the North American Prodrome Longitudinal Study (NAPLS 2) 199 cohort [36,38,41] and for the EU Gene-Environment Interaction (EU-GEI) study [15,16,42]. 200 Two studies were developed models in participants of the Vienna omega-3 randomised-201 controlled trial [37,39]. There was one model developed in the Personalised Prognostic Tools 202 for Early Psychosis Management (PRONIA) study [17], one model developed in a Korean 203 cohort study [40], one model developed in participants recruited from the Outreach and 204 Support in South London high-risk service [43], and one validated in the ICAAR (Influence of 205 Cannabis in the emergence of psychopathological symptoms in Adolescents and Adults at-206 Risk) study [47].

Mean study participant ages ranged from 15.8 years to 24.6 years. The majority of studies (16/17) defined participants at increased risk of psychosis through use of the SIPS (ten studies), CAARMS (four studies) or CAARMS-equivalent (two studies) criteria. A wide range of biomarkers were assessed including cytokines (four studies), single-nucleotide polymorphisms (SNPs; four studies), hormonal, inflammatory and metabolic-related analytes (two studies), ribonucleic acids (two studies), lipids (two studies), proteins (one study), metabolites (one study), and glutathione (one study) (Table 1).

Of the 16 development studies, nine internally validated model performance, of which five accounted for optimism in their performance estimates [15,17,41]. Four studies which used internal validation did not include the predictor selection process within the internal validation procedure. The remaining seven studies reported apparent performance (Table 1). Reported C-indices for logistic regression models ranged from 0.67-1.00. Reported C-indices for cox models ranged from 0.82-0.88. One study reported a balanced accuracy of 46.2%. None of

Review: predicting psychosis using blood biomarkers

the studies reported calibration measures or assessed clinical utility of their models. Further characteristics and performance metrics of the included studies are detailed in the Supplementary Material.

223

224 Risk of Bias and Applicability Assessments of Included Studies

All studies included in the systematic review were at high overall risk of bias according to PROBAST criteria. This was related to risk of bias in the analysis domain (Figure 2; Supplementary Table 3).

The risk of bias due to the selection of participants was rated unclear in ten out of 17 studies (58.8%). Generally, this related to either a lack of reporting of exclusion criteria used, a lack of comparison between included and excluded participants, or a lack of reporting of how many exclusions were made due to potentially inappropriate criteria (such as abnormal levels of blood parameters). Regarding applicability concerns in this domain, for the same reasons it was unclear in ten studies (58.8%) whether participants matched the review question (Figure 3).

Risk of bias due to the predictors or their assessment was unclear for 12 out of 17 studies (70.6%) as they did not report whether predictor assessments were made blind to the outcome data. The method of predictor assessment used in four studies (23.5%) may not match the review question, as it was unclear if the biomarker measurement methods used provide absolute quantification. A lack of standardised units for the biomarker measurement could hinder the generalisability of models. There were low applicability concerns for the remaining 13 studies in this applicability domain.

Risk of bias introduced by the outcome or its determination was low for 11 studies which used standard measures or structured interviews. Risk of bias introduced by the outcome was unclear for six studies (35.3%), largely because insufficient information on how the outcome was determined was reported. There were generally low concerns regarding the applicability

Review: predicting psychosis using blood biomarkers

of the outcome, with one study rated unclear in this domain, as the timing of the outcomedetermination relative to collection of the blood sample was unclear.

248 All studies were at high risk of bias in the analysis domain. None of the studies reported 249 measures of model calibration. Generally, studies did not have a sufficient number of 250 participants with the outcome or had a low number of events per candidate predictor. 9/16 251 development studies (56.3%) had less than one event per candidate predictor, and 14/16 252 (87.5%) had less than three events per candidate predictor. The one model validation study 253 had a sample size of 76. However, we calculated that with the given study outcome prevalence 254 of 0.237 and expected external validation C-index of 0.80, the minimum recommended sample 255 size for precise estimation of model performance metrics on external validation would be 709. 256 [33,48,49]. 5/16 (31.3%) development studies accounted for model overfitting and optimism 257 in performance estimates. Four of these studies used cross-validation for internal validation 258 and penalised regression models to shrink coefficients. One of these studies used the 259 bootstrap for internal validation and shrinkage. Other limitations included not accounting for 260 subsampling of controls, not reporting how missing data was handled or the use of univariable 261 analysis to select predictors for inclusion in the model.

262

263 Narrative Synthesis

264 None of the included studies assessed model calibration, a key metric for which a model must 265 perform acceptably if it is to be used to determine whether an intervention should be offered 266 [29]. The logistic regression model C-indices in model development studies which did not 267 account for optimism in their performance estimates ranged from 0.81 to 1 (with one study 268 reporting a cox model C-index of 0.82). Model development studies which accounted for 269 optimism in their performance estimates reported C-indices from logistic regression models 270 ranging from 0.67-0.95 (with one study reporting a cox model C-index of 0.88 and one study 271 reporting a balanced accuracy of 46.2%).

Review: predicting psychosis using blood biomarkers

272 Three studies which adjusted their performance estimates for optimism used polygenic risk 273 scores (PRS) as a blood-based predictors [17,41,43]. Perkins et al. [41] investigated adding 274 PRS to an established cox regression model comprised of clinical predictors. When PRS was 275 included as a variable together with the clinical predictors, there was no evidence from a 276 likelihood ratio chi-square test that the PRS added predictive value. Furthermore, the C-index 277 was unchanged for participants of non-European descent and was similar for participants of 278 European descent (point estimate increase of 0.01). In line with this, Koutsouleris et al. [17] 279 found that a model based on PRS variables had a similar C-index to that achieved by 280 predictions from clinical raters, and Tavares et al. [43] found that a PRS model did not 281 discriminate between individuals who transitioned and did not transition better than chance.

282 The final model presented by Chan et al. [47] and the "15-analyte" model in Perkins et al. [36] 283 had two overlapping predictors, Interleukin-8 and Factor VII. While model coefficients were 284 not available in Perkins et al. [36], the two studies presented the same direction of effect for 285 IL-8 and opposite directions of effect for Factor VII in univariate analyses. Zhang et al. [46] 286 and Mondelli et al [42] did not find evidence for the predictive ability of IL-8 for transition to 287 psychotic disorder. Zhang et al. 2022 [44], Zhang et al. 2023a [45] and Mondelli et al. [42] all 288 included different cytokine ratios in their models (IL-1β/IL-6, IL-2/IL-6 and IL-10/IL-6 289 respectively) with the aim of capturing inflammatory balance. Chan et al. [47] and Mongan et 290 al. [15] both included Alpha-2-Macroglobulin as a predictor in their final models, though 291 coefficients were in opposite directions. No other overlapping predictors were noted between 292 final models presented in studies.

293

294 Discussion

We undertook a focused systematic review of models predicting transition to psychosis with use of recent guidelines for systematically reviewing prognostic models [31,50]. Models developed with blood biomarkers require unique consideration, as any predictive benefit of

Review: predicting psychosis using blood biomarkers

298 blood biomarkers over clinical predictors must outweigh the disadvantages associated with 299 their measurement, namely the cost or potential lack of wide accessibility. While studies 300 included in this review described a wide range of blood biomarkers that potentially have altered 301 concentrations preceding psychosis, the prognostic models including blood biomarkers were 302 not developed according to the latest methodological recommendations, lacked calibration and lacked sufficient external validation. Therefore, similar to recent systematic reviews of 303 304 prediction models in psychiatry [20,51,52], we did not find evidence for a model suitable for 305 implementation into clinical practice [53].

306 As all the studies were rated at high risk of bias, we are unable to recommend a particular 307 model to be externally validated, and it is unclear at the present time whether any specific 308 blood biomarkers could potentially contribute to improved prediction of transition to psychosis 309 in individuals at risk. However, evidence from three studies suggested that models including 310 polygenic risk scores do not sufficiently outperform models based on clinical variables or 311 clinical rater predictions. A wide range of other biomarkers were assessed in the included 312 studies, however, going forward, the field will need to externally validate models to truly 313 estimate their generalizability. Risk prediction models cannot be recommended for clinical 314 practice without sufficient external validation.

315 In general, the reporting of study design and methods could be improved in the field. We 316 recommend that future studies follow the transparent reporting of a multivariable prediction 317 model for individual prognosis or diagnosis (TRIPOD) reporting guidelines [54] and explicitly 318 report on participant exclusion criteria and whether predictors were assessed blind to outcome 319 status. Blood-biomarkers in cohort studies are often assessed after the outcome is determined 320 and therefore studies involving blood-biomarkers are at particular risk of bias in this domain. 321 As well as blinding, studies should report whether samples were randomised prior to 322 biomarker measurement. Recent guidance proposes block randomisation as a gold standard 323 [55,56].

Review: predicting psychosis using blood biomarkers

324 Sixteen out of the 17 studies in this review defined their participants to be at risk of psychosis 325 through use of SIPS and CAARMS interviews for prodromal symptoms or reduced functioning 326 combined with genetic risk. While these established "clinical-high risk" and "at-risk mental 327 state" constructs are risk-enriched populations with an estimated 2-year transition rate of 19% 328 [7], they may only capture a minority (4-14%) of the population who present with a first episode 329 of psychosis, indicating a relatively poor predictive capacity [57-59]. There have been recent 330 calls to expand the clinical high risk paradigm such as to include individuals attending child 331 and adolescent mental health services or presenting to emergency departments due to self-332 harm, as they are at similar risk of psychosis [60-62]. This "systems approach" may capture 333 a greater proportion of first episode psychosis cases than prodromal constructs. We 334 recommend that future studies are designed in populations with a higher predictive capacity 335 for psychosis [62], as this may help to mitigate issues with insufficient sample sizes in the field 336 and potential recruitment bias.

337 Some of the studies in this review excluded participants based on established psychiatric 338 diagnoses or when a participant's prodromal symptoms were caused by a mood or anxiety 339 disorder. In light of studies showing that psychotic symptoms are highly prevalent in disorders 340 of depression and anxiety [63] and that psychosis can be predicted in individuals with non-341 psychotic mental illnesses [64–66], these may be inappropriate exclusion criteria. On the other 342 hand, a more nuanced assessment of clinical and biological risk factors associated with 343 psychosis, such as minimal self [67], circadian rhythms [68] or trait-like EEG signatures [69], 344 could be used to reduce biological heterogeneity. Reducing biological heterogeneity could 345 complement traditional risk-enrichment approaches and allow for the identification of more 346 replicable blood biomarkers of psychosis risk.

Half of the studies included in this systematic review considered over 100 candidate predictors. With the growing popularity of "omics" methods, it must be highlighted that the latest research does not suggest that data-driven methods of predictor selection involving the outcome data can alleviate overfitting in situations of high dimensionality and low sample size.

Review: predicting psychosis using blood biomarkers

Univariable screening has long been highlighted as problematic [70]. Multivariable selection methods such as LASSO have recently been shown to be unstable in small sample sizes or with small numbers of events [71]. Researchers should be aware that penalisation methods do not solve the issue of a small ratio of events to predictors. Sample size calculators for the development or validation of prediction models with binary or time-to-event outcomes are now easily accessible and should be utilised prior to designing studies to ensure adequate power [49,72,73].

358 One of the main limitations of the studies in the analysis domain was the lack of calibration of 359 models. In the first instance, clinical prediction models must produce predicted event 360 probabilities for each individual rather than binary event or non-event predictions alone - for a 361 model to be implemented into clinical practice, a probability cut-off relating to maximum clinical 362 benefit is required to determine whether a specific intervention should be offered or not 363 [22,30,74]. Calibration measures how well the predicted probabilities match the observed 364 proportion of outcomes, i.e. the accuracy of risk estimates, and models can have poor 365 calibration even when models show good discrimination. An over- or underestimation of the 366 probability of developing a psychotic disorder is ethically unacceptable, and would lead to 367 inappropriately offered interventions or undertreatment [29]. Future studies in the field should 368 assess model calibration to improve the chances of models being implemented clinically.

369 The studies included in this review had further limitations in the analysis domain. Some studies 370 did not handle missing data to PROBAST standards. Missing biomarker data is often related 371 to biomarker concentrations being below the limit of detection. In this case, the data should 372 be considered missing not-at-random. PROBAST guidelines recommend multiple imputation 373 as best practice in prediction modelling [31], and solutions combining multiple imputation with 374 left-censored missing data have been proposed [75]. Furthermore, participant subsampling 375 was frequent. When subsampling is necessary, researchers should weight cases and controls 376 by the inverse of their sampling fractions in analyses [28].

Review: predicting psychosis using blood biomarkers

377 This review has several strengths. The review has benefitted from prospective registration and 378 the use of recommended reporting guidelines [23], search strategies [25], data extraction tools 379 [27] and risk of bias assessment tools [30]. However, there are also several limitations to this 380 review. We were unable to perform meta-analyses as we did not identify any models that were 381 externally validated multiple times. Meta-analyses of models with different predictors or 382 validation approaches would not have been readily interpretable. Due to limitations of the 383 modelling strategies in the studies and lack of external validation of models, we were not able 384 to perform a head-to-head comparison of the performance of each of the prediction models 385 as the performance estimates were at high risk of bias. Finally, we acknowledge that the 386 concept of a binary "transition" to psychosis, even in the presence of assessment criteria, can 387 be subjective or can sometimes represent small increases in the severity or frequency of symptoms [76]. This review did not examine the prediction of positive symptoms as continuous 388 389 outcomes, which may be worth examining in future reviews in the field.

390 In conclusion, while there have been several studies developing models using blood-based 391 biomarkers for prediction of transition to psychotic disorder, this review found no models that 392 are ready for implementation in clinical practice, and the value of including blood-based 393 biomarkers in models predicting transition to psychosis is unclear due to the high risk of bias 394 of the eligible studies. The field of prediction modelling is rapidly progressing and it should be 395 noted that new methodological recommendations have been made since the majority of the 396 studies in this review were published [71,72]. Future studies should aim to follow the latest 397 available reporting guidelines, assess model calibration, internally and repeatedly externally 398 validate models, and adopt strategies to accommodate minimum required sample sizes in 399 order to maximise potential clinical benefits and outcomes for patients.

400

401 Registration and Protocol

402 This systematic review was prospectively registered with PROSPERO, CRD42022302047.

Review: predicting psychosis using blood biomarkers

403 Funding

404 D.R.C., M.F. and J.F.B. are supported by a Wellcome Flagship Innovations Award (IMPETUS) 405 - 220438Z/20/Z). D.R.C. is supported by a Health Research Board Investigator Led Project 406 Grant (ILP-POR-2017-039), M.C. is supported by a European Research Council Consolidator 407 Award (iHEAR 724809), C.H. is supported by Health Research Board Investigator Led Project 408 Grant (ILP-PHR-2019-009), D.M. is a Fellow on the Irish Clinical Academic Training (ICAT) Programme which is supported by the Wellcome Trust and the Health Research Board (Grant 409 410 Number 203930/B/16/Z), the Health Service Executive National Doctors Training and 411 Planning and the Health and Social Care, Research and Development Division, Northern 412 Ireland. S.R.S is supported by the Health Research Board (HRB) under grant number 413 HRB/HRA/PHR/2015-1293. D.R.C and J.F.B are supported in part by Science Foundation 414 Ireland (SFI) under Grant Number 16/RC/3948 and co-funded under the European Regional 415 Development Fund and by FutureNeuro industry partners.

416 **Conflict of Interest**

D.M., M.C. and D.R.C. report a patent pending (UK Patent Application No. 1919155.0,
"Biomarkers to predict psychosis"). C.H., M.F., J.M. and J.F.B. report no financial relationships
with commercial interests.

420

421 **References**

422 1. Riecher-Rössler A, Studerus E. Prediction of conversion to psychosis in individuals with an at-

423 risk mental state: a brief update on recent developments. Current Opinion in Psychiatry.

- 424 2017;30:209–219.
- Sanfelici R, Dwyer DB, Antonucci LA, Koutsouleris N. Individualized Diagnostic and Prognostic
 Models for Patients With Psychosis Risk Syndromes: A Meta-analytic View on the State of the
 Art. Biological Psychiatry. 2020;88:349–360.
- Montemagni C, Bellino S, Bracale N, Bozzatello P, Rocca P. Models predicting psychosis in
 patients with high clinical risk: a systematic review. Frontiers in Psychiatry. 2020;11:223.

430	4.	Yung AR, Yung AR, Pan Yuen H, Mcgorry PD, Phillips LJ, Kelly D, et al. Mapping the onset of
431		psychosis: the comprehensive assessment of at-risk mental states. Australian & New Zealand
432		Journal of Psychiatry. 2005;39:964–971.
433	5.	Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodromal
434		assessment with the structured interview for prodromal syndromes and the scale of prodromal
435		symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia
436		Bulletin. 2003;29:703–715.
437	6.	Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, et al.
438		The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review. JAMA Psychiatry.
439		2013;70:107–120.
440	7.	Salazar de Pablo G, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F, et al. Probability of
441		Transition to Psychosis in Individuals at Clinical High Risk: An Updated Meta-analysis. JAMA
442		Psychiatry. 2021;78:970–978.
443	8.	Fraguas D, Díaz-Caneja CM, Rodríguez-Quiroga A, Arango C. Oxidative stress and inflammation
444		in early onset first episode psychosis: a systematic review and meta-analysis. International
445		Journal of Neuropsychopharmacology. 2017;20:435–444.
446	9.	Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first
447		episode psychosis: a systematic review and meta-analysis. Schizophrenia Research.
448		2014;155:101–108.
449	10.	Perry BI, McIntosh G, Weich S, Singh S, Rees K. The association between first-episode psychosis
450		and abnormal glycaemic control: systematic review and meta-analysis. The Lancet Psychiatry.
451		2016;3:1049–1058.
452	11.	Mongan D, Healy C, Jones HJ, Zammit S, Cannon M, Cotter DR. Plasma polyunsaturated fatty
453		acids and mental disorders in adolescence and early adulthood: cross-sectional and
454		longitudinal associations in a general population cohort. Translational Psychiatry. 2021;11:1-
455		13.
456	12.	Perry BI, Stochl J, Upthegrove R, Zammit S, Wareham N, Langenberg C, et al. Longitudinal
457		Trends in Childhood Insulin Levels and Body Mass Index and Associations With Risks of
458		Psychosis and Depression in Young Adults. JAMA Psychiatry. 2021;78:416–425.
459	13.	Osimo EF, Baxter L, Stochl J, Perry BI, Metcalf SA, Kunutsor SK, et al. Longitudinal association
460		between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies.
461		Npj Schizophrenia. 2021;7:31.

Review: predicting psychosis using blood biomarkers

462	14.	Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, et al. A meta-review of
463		"lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and
464		treatment of mental disorders. World Psychiatry. 2020;19:360–380.
465	15.	Mongan D, Föcking M, Healy C, Susai SR, Heurich M, Wynne K, et al. Development of proteomic
466		prediction models for transition to psychotic disorder in the clinical high-risk state and
467		psychotic experiences in adolescence. JAMA Psychiatry. 2021;78:77–90.
468	16.	Dickens AM, Sen P, Kempton MJ, Barrantes-Vidal N, Iyegbe C, Nordentoft M, et al.
469		Dysregulated lipid metabolism precedes onset of psychosis. Biological Psychiatry.
470		2021;89:288–297.
471	17.	Koutsouleris N, Dwyer DB, Degenhardt F, Maj C, Urquijo-Castro MF, Sanfelici R, et al.
472		Multimodal machine learning workflows for prediction of psychosis in patients with clinical
473		high-risk syndromes and recent-onset depression. JAMA Psychiatry. 2021;78:195–209.
474	18.	Li Z, Zhang T, Xu L, Wei Y, Cui H, Tang Y, et al. Plasma metabolic alterations and potential
475		biomarkers in individuals at clinical high risk for psychosis. Schizophrenia Research.
476		2022;239:19–28.
477	19.	Song W, Xu L, Zhang T, Wang W, Fu Y, Xu Q, et al. Peripheral transcriptome of clinical high-risk
478		psychosis reflects symptom alteration and helps prognosis prediction. Psychiatry and Clinical
479		Neurosciences. 2022. 2022.
480	20.	Meehan AJ, Lewis SJ, Fazel S, Fusar-Poli P, Steyerberg EW, Stahl D, et al. Clinical prediction
481		models in psychiatry: a systematic review of two decades of progress and challenges.
482		Molecular Psychiatry. 2022;27:2700–2708.
483	21.	Studerus E, Ramyead A, Riecher-Rössler A. Prediction of transition to psychosis in patients with
484		a clinical high risk for psychosis: a systematic review of methodology and reporting.
485		Psychological Medicine. 2017;47:1163–1178.
486	22.	Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis
487		Research Strategy (PROGRESS) 3: prognostic model research. PLoS Medicine.
488		2013;10:e1001381.
489	23.	Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, et al. Transparent reporting of
490		multivariable prediction models for individual prognosis or diagnosis: checklist for systematic
491		reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538.
492	24.	Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, et al. Prediction of
493		psychosis: a step towards indicated prevention of schizophrenia. The British Journal of
494		Psychiatry. 1998;172:14–20.

495	25.	Geersing G-J, Bouwmeester W, Zuithoff P, Spijker R, Leeflang M, Moons K. Search filters for
496		finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews.
497		PloS One. 2012;7:e32844.
498	26.	Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search
499		results for systematic reviews in EndNote. Journal of the Medical Library Association: JMLA.
500		2016;104:240.
501	27.	Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical
502		appraisal and data extraction for systematic reviews of prediction modelling studies: the
503		CHARMS checklist. PLoS Medicine. 2014;11:e1001744.
504	28.	Harrell Jr FE. Regression Modeling Strategies With Applications to Linear Models, Logistic and
505		Ordinal Regression, and Survival Analysis. 2nd ed. Springer Cham; 2015.
506	29.	Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW, Bossuyt P, et al.
507		Calibration: the Achilles heel of predictive analytics. BMC Medicine. 2019;17:230.
508	30.	Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool
509		to Assess the Risk of Bias and Applicability of Prediction Model Studies. Ann Intern Med.
510		2019;170:51–58.
511	31.	Moons KG, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to
512		assess risk of bias and applicability of prediction model studies: explanation and elaboration.
513		Annals of Internal Medicine. 2019;170:W1–W33.
514	32.	McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web
515		app for visualizing risk-of-bias assessments. Research Synthesis Methods. 2021;12:55–61.
516	33.	Pavlou M, Qu C, Omar RZ, Seaman SR, Steyerberg EW, White IR, et al. Estimation of required
517		sample size for external validation of risk models for binary outcomes. Stat Methods Med Res.
518		2021;30:2187–2206.
519	34.	Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct
520		of narrative synthesis in systematic reviews. A Product from the ESRC Methods Programme
521		Version. 2006;1:b92.
522	35.	Debray TP, Damen JA, Riley RD, Snell K, Reitsma JB, Hooft L, et al. A framework for meta-
523		analysis of prediction model studies with binary and time-to-event outcomes. Statistical
524		Methods in Medical Research. 2019;28:2768–2786.
525	36.	Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, et al. Towards a
526		psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary
527		results from the NAPLS project. Schizophr Bull. 2015;41:419–428.

528	37.	Clark S, Baune B, Schubert K, Lavoie S, Smesny S, Rice S, et al. Prediction of transition from
529		ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical
530		assessment and fatty-acid biomarkers. Translational Psychiatry. 2016;6:e897–e897.
531	38.	Jeffries C, Perkins D, Chandler S, Stark T, Yeo E, Addington J, et al. Insights into psychosis risk
532		from leukocyte microRNA expression. Translational Psychiatry. 2016;6:e981–e981.
533	39.	Lavoie S, Berger M, Schlögelhofer M, Schäfer M, Rice S, Kim S, et al. Erythrocyte glutathione
534		levels as long-term predictor of transition to psychosis. Translational Psychiatry. 2017;7:e1064–
535		e1064.
536	40.	Bousman CA, Lee TY, Kim M, Lee J, Mostaid MS, Bang M, et al. Genetic variation in cytokine
537		genes and risk for transition to psychosis among individuals at ultra-high risk. Schizophrenia
538		Research. 2018;195:589–590.
539	41.	Perkins DO, Olde Loohuis L, Barbee J, Ford J, Jeffries CD, Addington J, et al. Polygenic risk score
540		contribution to psychosis prediction in a target population of persons at clinical high risk.
541		American Journal of Psychiatry. 2020;177:155–163.
542	42.	Mondelli V, Blackman G, Kempton MJ, Pollak TA, Iyegbe C, Valmaggia LR, et al. Serum immune
543		markers and transition to psychosis in individuals at clinical high risk. Brain, Behavior, and
544		Immunity. 2023;110:290–296.
545	43.	Tavares V, Vassos E, Marquand A, Stone J, Valli I, Barker GJ, et al. Prediction of transition to
546		psychosis from an at-risk mental state using structural neuroimaging, genetic, and
547		environmental data. Frontiers in Psychiatry. 2022;13.
548	44.	Zhang T, Zeng J, Wei Y, Ye J, Tang X, Xu L, et al. Changes in inflammatory balance correlates
549		with conversion to psychosis among individuals at clinical high-risk: A prospective cohort study.
550		Psychiatry Research. 2022;318:114938.
551	45.	Zhang T, Wei Y, Zeng J, Ye J, Tang X, Xu L, et al. Interleukin-2/interleukin-6 imbalance correlates
552		with conversion to psychosis from a clinical high-risk state. Psychiatry and Clinical
553		Neurosciences. 2023;77:62–63.
554	46.	Zhang T, Zeng J, Ye J, Gao Y, Hu Y, Xu L, et al. Serum complement proteins rather than
555		inflammatory factors is effective in predicting psychosis in individuals at clinical high risk.
556		Translational Psychiatry. 2023;13:9.
557	47.	Chan MK, Krebs M, Cox D, Guest P, Yolken R, Rahmoune H, et al. Development of a blood-
558		based molecular biomarker test for identification of schizophrenia before disease onset.
559		Translational Psychiatry. 2015;5:e601–e601.
560	48.	Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of
561		a multivariable prognostic model: a resampling study. Statistics in Medicine. 2016;35:214–226.

562	49.	Riley RD, Debray TPA, Collins GS, Archer L, Ensor J, van Smeden M, et al. Minimum sample size
563		for external validation of a clinical prediction model with a binary outcome. Statistics in
564		Medicine. 2021;40:4230–4251.
565	50.	Damen JAA, Moons KGM, van Smeden M, Hooft L. How to conduct a systematic review and
566		meta-analysis of prognostic model studies. Clinical Microbiology and Infection.
567		https://doi.org/10.1016/j.cmi.2022.07.019.
568	51.	Moriarty AS, Meader N, Snell KI, Riley RD, Paton LW, Dawson S, et al. Predicting relapse or
569		recurrence of depression: systematic review of prognostic models. The British Journal of
570		Psychiatry. 2022:1–11.
571	52.	Lee R, Leighton SP, Thomas L, Gkoutos GV, Wood SJ, Fenton S-JH, et al. Prediction models in
572		first-episode psychosis: systematic review and critical appraisal. The British Journal of
573		Psychiatry. 2022:1–13.
574	53.	Wallace E, Smith SM, Perera-Salazar R, Vaucher P, McCowan C, Collins G, et al. Framework for
575		the impact analysis and implementation of Clinical Prediction Rules (CPRs). BMC Medical
576		Informatics and Decision Making. 2011;11:62.
577	54.	Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable
578		prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Journal
579		of British Surgery. 2015;102:148–158.
580	55.	Burger B, Vaudel M, Barsnes H. Importance of block randomization when designing proteomics
581		experiments. Journal of Proteome Research. 2020;20:122–128.
582	56.	Qin L-X, Zhou Q, Bogomolniy F, Villafania L, Olvera N, Cavatore M, et al. Blocking and
583		Randomization to Improve Molecular Biomarker DiscoveryBlocking and Randomization for
584		Biomarker Discovery. Clinical Cancer Research. 2014;20:3371–3378.
585	57.	Lång U, Yates K, Leacy FP, Clarke MC, McNicholas F, Cannon M, et al. Systematic Review and
586		Meta-analysis: Psychosis Risk in Children and Adolescents With an At-Risk Mental State.
587		Journal of the American Academy of Child & Adolescent Psychiatry. 2022;61:615–625.
588	58.	Ajnakina O, Morgan C, Gayer-Anderson C, Oduola S, Bourque F, Bramley S, et al. Only a small
589		proportion of patients with first episode psychosis come via prodromal services: a
590		retrospective survey of a large UK mental health programme. BMC Psychiatry. 2017;17:1–9.
591	59.	Burke T, Thompson A, Mifsud N, Yung AR, Nelson B, McGorry P, et al. Proportion and
592		characteristics of young people in a first-episode psychosis clinic who first attended an at-risk
593		mental state service or other specialist youth mental health service. Schizophrenia Research.
594		2022;241:94–101.

595	60.	Bolhuis K, Lång U, Gyllenberg D, Kääriälä A, Veijola J, Gissler M, et al. Hospital presentation for
596		self-harm in youth as a risk marker for later psychotic and bipolar disorders: a cohort study of
597		59 476 Finns. Schizophrenia Bulletin. 2021;47:1685–1694.
598	61.	Lång U, Ramsay H, Yates K, Veijola J, Gyllenberg D, Clarke MC, et al. Potential for prediction of
599		psychosis and bipolar disorder in Child and Adolescent Mental Health Services: a longitudinal
600		register study of all people born in Finland in 1987. World Psychiatry. 2022;21:436–443.
601	62.	Cotter D, Healy C, Staines L, Mongan D, Cannon M. Broadening the parameters of clinical high
602		risk for psychosis. American Journal of Psychiatry. 2022;179:593–595.
603	63.	Wigman JT, van Nierop M, Vollebergh WA, Lieb R, Beesdo-Baum K, Wittchen H-U, et al.
604		Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression,
605		impacting on illness onset, risk, and severity—implications for diagnosis and ultra-high risk
606		research. Schizophrenia Bulletin. 2012;38:247–257.
607	64.	Fusar-Poli P, Rutigliano G, Stahl D, Davies C, Bonoldi I, Reilly T, et al. Development and
608		Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis.
609		JAMA Psychiatry. 2017;74:493–500.
610	65.	Fusar-Poli P, Werbeloff N, Rutigliano G, Oliver D, Davies C, Stahl D, et al. Transdiagnostic Risk
611		Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis:
612		Second Replication in an Independent National Health Service Trust. Schizophrenia Bulletin.
613		2019;45:562–570.
614	66.	Oliver D, Wong CMJ, Bøg M, Jönsson L, Kinon BJ, Wehnert A, et al. Transdiagnostic
615		individualized clinically-based risk calculator for the automatic detection of individuals at-risk
616		and the prediction of psychosis: external replication in 2,430,333 US patients. Translational
617		Psychiatry. 2020;10:364.
618	67.	Martin B, Wittmann M, Franck N, Cermolacce M, Berna F, Giersch A. Temporal structure of
619		consciousness and minimal self in schizophrenia. Frontiers in Psychology. 2014;5.
620	68.	Lunsford-Avery JR, Gonçalves B da SB, Brietzke E, Bressan RA, Gadelha A, Auerbach RP, et al.
621		Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened
622		prognosis at 1-year follow-up. Schizophrenia Research. 2017;189:37–42.
623	69.	Clementz BA, Parker DA, Trotti RL, McDowell JE, Keedy SK, Keshavan MS, et al. Psychosis
624		Biotypes: Replication and Validation from the B-SNIP Consortium. Schizophrenia Bulletin.
625		2022;48:56–68.
626	70.	Sun G-W, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for
627		use in multivariable analysis. Journal of Clinical Epidemiology. 1996;49:907–916.

Review: predicting psychosis using blood biomarkers

- 628 71. Riley RD, Snell KIE, Martin GP, Whittle R, Archer L, Sperrin M, et al. Penalization and shrinkage
- 629 methods produced unreliable clinical prediction models especially when sample size was small.
- 630 Journal of Clinical Epidemiology. 2021;132:88–96.
- Riley RD, Ensor J, Snell KI, Harrell FE, Martin GP, Reitsma JB, et al. Calculating the sample size
 required for developing a clinical prediction model. Bmj. 2020;368.
- Riley RD, Snell KI, Ensor J, Burke DL, Harrell Jr FE, Moons KG, et al. Minimum sample size for
 developing a multivariable prediction model: PART II binary and time-to-event outcomes.
- 635 Statistics in Medicine. 2019;38:1276–1296.
- 636 74. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision
 637 curve analysis. Diagnostic and Prognostic Research. 2019;3:18.
- 638 75. Gardner ML, Freitas MA. Multiple Imputation Approaches Applied to the Missing Value
- 639 Problem in Bottom-Up Proteomics. International Journal of Molecular Sciences. 2021;22.
- 640 76. van Os J, Guloksuz S. A critique of the "ultra-high risk" and "transition" paradigm. World
 641 Psychiatry. 2017;16:200–206.

- 643
- 644

Review: predicting psychosis using blood biomarkers

645 Figure 1: PRISMA flow diagram of study selection.

646

647 Table 1: Study Characteristics


- 648 Structured Interview for Psychosis Risk Syndromes (SIPS), Comprehensive Assessment of At-Risk
- 649 Mental State (CAARMS), Social and Occupational Functioning Assessment Scale (SOFAS), micro-
- 650 ribonucleic acid (miRNA), single-nucleotide polymorphisms (SNPs), least-absolute shrinkage and
- 651 selection operator (LASSO), support vector machine (SVM), bayesian generalised linear model
- 652 (bayesglm), logistic regression (LR), leave one site out cross-validation (LOSOCV).

653

Figure 2: Results of risk of bias assessments in each domain.

655

Figure 3: Summary of applicability concerns in each domain.



Study		Clark et al., 2016	Dickens et al., 2021	Chan et al., 2015	Jeffries et al., 2016	Koutsouleris et al., 2021	Lavoie et al., 2017		Mondelli et al 2023	Mongan et al., 2021	Perkins et al., 2015	Perkins et al., 2020	Song et al., 2022	Tavares et al. 2023	Zhang et al., 2022	Zhang et al., 2023a	Zhang et al., 2023b
Type of study	Model Development	Model Development	Model Development	Model Validation	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development	Model Development
Study design	Cohort	RCT	Cohort	Cohort	Cohort	Cohort	RCT	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort	Cohort
Study setting	gOutpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient	Outpatient
Location	Korea	Austria	International	France	North America	Europe	Austria	China	International	International	North America	North America	China	United Kingdom	China	China	China
N =	134	40	263	76	67	201	36	90	269	133	72	595	56	75	84	37	49
			L														
N transitions N	20	11	50	18	30	25	15	23	50	49	32	84	NI	21	16	8	25
(transitions)																	
for external validation	N/A	N/A	N/A	76 (18)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Age, mean						NI (full plus 18M cohort											
(SD):	21 (4)	16 (1.7)	22.5 (4.8)	21.5 (3.9)	18.4 (3.7)	24.6 (5.6))	15.8 (1.8)	18.1 (4.4)	22.6 (4.9)	22.8 (4.5)	19.4 (4.2)	18.5 (4.3)	17.7 (4.2)	22.9 (4.4)	18.5 (5.2)	17.6 (3.7)	18.2 (4.1)
Sex, n (%						NI (full plus 18M cohort											
female):	85 (63.4%)	27 (67.5%)	122 (46.4%)	32 (42.1%)	22 (32.8%)	51.6%)	25 (69.4%)	38 (42.2%)	122 (45.4%)	65 (48.9%)	25 (34.7%)	251 (42.2%)	25 (44.6%)	31 (41.3%)	35 (41.7%)	18 (48.6%)	14 (28.6%)
Method of risk assessment	SIPS	CAARMS- equivalent	CAARMS	SOFAS; N/A	SIPS	SIPS	CAARMS- equivalent	SIPS	CAARMS	CAARMS	SIPS	SIPS	SIPS	CAARMS	SIPS	SIPS	SIPS
No. of events per	genes	Fatty acids	Lipidome	Hormonal, inflammatory and metabolic related analytes	Leukocyte	Genome	Glutathione	Metabolome	Cytokines	Proteome	Hormonal, inflammatory and metabolic- related analytes	Genome	Transciptome	Genome	Cytokines	Cytokines	Cytokines and complement proteins
candidate predictor	0.87	0.55	5 0.29	0.78	0.22	1.25	5 15	0.0012	1.85	0.2	0.27	9.33	0.00053	3 21	16	2.67	1.39
Modelling method	Crosstab/Logi stic		Ridge Regression	LASSO	Coarse approximate linear	SVM	Cox regression		Elastic Net	SVM	Coarse approximate linear classifier		LASSO	Elastic Net Regression	Logistic regression	Logistic	Logistic regression
Method used for testing model performance		Apparent	Internal	External	Internal	Internal- external (geographical)	Apparent	Apparent	Internal	Internal- external (geographical)	Internal	Internal	Internal	Internal	Apparent	Apparent	Apparent
Type of internal	, por anc	- pparate				Nested cross validation	- pharant			Nested cross validation					- phone in		- pp. ar and
validation if	NZA	NZA	Poststran	NZA	Cross	(outer:	NIA	NZA	Cross	(outer:	Cross	Pootstran	Cross	Cross	NZA	N/A	NZA
used	N/A	N/A	Bootstrap	N/A	validation	LOSOCV)	N/A	N/A	validation	LOSOCV)	validation	Bootstrap	validation	validation	N/A	N/A	N/A

			Ris	sk of bias domair	IS					
Ĩ		D1	D2	D3	D4	Overall				
	Bousman et al., 2018	-	-	+	X	×				
	Chan et al., 2015	-	+	-	×	×				
	Clark et al., 2016	-	-	-	×	X				
	Dickens et al., 2021	+	-	-	×	X				
	Jeffries et al., 2016	-	-	+	×	X				
	Koutsouleris et al., 2021	+	-	+	×	X				
	Lavoie et al., 2017	-	+	+	×	X				
	Li et al., 2022	-	-	+	×	X				
Study	Mondelli et al., 2023	+	+	-	X	X				
	Mongan et al., 2020	+	+	-	×	X				
	Perkins et al., 2016	-	-	+	×	×				
	Perkins et al., 2017	-	+	+	×	X				
	Song et al., 2022	-	-	-	×	X				
	Tavares et al., 2023	+	-	+	×	X				
	Zhang et al., 2022	+	-	+	×	×				
	Zhang et al., 2023a	+	-	+	X	X				
	Zhang et al., 2023b	-	-	+	×	X				
		Domains:		- f	Judg	ement				
		D2: Bias introdu	D1: Bias introduced by selection of participants. D2: Bias introduced by predictors or their assessment. D3: Bias introduced by the outcome or its determination							

D3: Bias introduced by the outcome or its determination. D4: Bias introduced by the analysis.

+

-

Low risk of bias

Unclear

		Applicabili	ty domains	
	D1	D2	D3	Overall
Bousman et al., 2018	-	+	+	-
Chan et al., 2015	-	+	-	-
Clark et al., 2016	-	+	+	-
Dickens et al., 2021	+	+	+	+
Jeffries et al., 2016	-	-	+	-
Koutsouleris et al., 2021	+	+	+	+
Lavoie et al., 2017	-	+	+	-
Li et al., 2022	-	-	+	-
Mondelli et al., 2023	+	+	+	+
Mongan et al., 2020	+	-	+	-
Perkins et al., 2016	-	+	+	-
Perkins et al., 2017	-	+	+	-
Song et al., 2022	-	-	+	-
Tavares et al., 2023	+	+	+	+
Zhang et al., 2022	+	+	+	+
Zhang et al., 2023a	+	+	+	+
Zhang et al., 2023b	-	+	+	-
	and setting.	cern regarding the inc cern regarding the de rs.		Judgement - Unclear + Low concern

or timing of predictors. D3: Applicability concern regarding the outcome, its definition, timing or determination.

Study